In this podcast, NTRK CONNECT members Prof Frédérique Penault-Llorca (University of Clermont-Ferrand, France) and Prof Andrea Sartore-Bianchi (Niguarda Cancer Centre, Milan, Italy) provide both a pathologist and medical oncologist perspective about the detection and treatment of TRK fusion-positive GI cancers, with a particular focus on colorectal cancer.
Penault-Llorca and Sartore-Bianchi start by explaining TRK fusion biology, the role as oncogenic drivers and briefly describe the two approved TRK inhibitors. They then discuss the challenges of finding patients harboring these fusions, referring to how enrichment strategies and predictors can aid identification in patients with GI cancers. Finally, they discuss key efficacy and safety data for larotrectinib and entrectinib, as well as mentioning second-generation products in development to tackle mechanisms of resistance.
Medical education: Join Lead Nurse Andreia Fernandes and Clinical Nurse Specialist Jo Pearson as they explain how to help patients navigate the side effects...
In this first episode of a three-episode podcast series, COR2ED and ASBMR have partnered with Professor Anna Teti (University of L’Aquila) to provide rare...
COR2ED Medical Education: This second GI CONNECT podcast episode, covers the highlights on gastroesophageal cancer from ESMO 2022. Dr Sam Klempner (Massachusetts General Hospital,...